Journal Information
Vol. 37. Issue 10.
Pages 407-409 (October 2001)
Vol. 37. Issue 10.
Pages 407-409 (October 2001)
Full text access
Oxidación celular y fármacos mucoactivos antioxidantes
Visits
10099
N. González-Mangadoa,
, J. Morera Pratb
Corresponding author
ngonzalez@fjd.es
Correspondencia: Jefe del Servicio de Neumología. Fundación Jiménez Díaz. Avda. Reyes Católicos, 2. 28040 Madrid
Correspondencia: Jefe del Servicio de Neumología. Fundación Jiménez Díaz. Avda. Reyes Católicos, 2. 28040 Madrid
This item has received
Article information
Full text is only aviable in PDF
Bibliografía
[1.]
T.S. Haugen, O.H. Skjonsberg, H. Kahler, T. Lyberg.
Production of oxidants in alveolar macrophages and blood leukocytes.
Eur Respir J, 14 (1999), pp. 1100-1105
[2.]
I. Rahman, W. MacNee.
Role of oxidants/antioxidants in smoking induced lung diseases.
Free Radic Biol Med, 21 (1996), pp. 669-681
[3.]
J.E. Repine, A. Bast, I. Lankhorst.
Oxidative stress in chronic obstructive pulmonary disease.
Am J Respir Crit Care Med, 156 (1997), pp. 341-357
[4.]
J.P. Barnes.
Chronic obstructive pulmonary disease.
N Engl J Med, 343 (2000), pp. 269-280
[5.]
M.L. Rubio, M. Ortega, M.V. Sanchez-Cifuentes, M.C. Martin Mosquero, G. Peces-Barba, N. Gonzalez Mangado.
Expression of extracelular matrix proteins and transforming growth factor-α in rats following exposure to cigarette smoke role of n-acetylcysteine.
Eur Respir J, 14 (1999), pp. S297
[6.]
P.N. Dekhuijzen, K.K. Aben, J. Dekker, L.P. Aarts, P.L. Wielders, C.L. Van Herwaarden, et al.
Increased exhalation of hydrogen peroxide in patients with stable and unstable chronic obstructive pulmonary disease.
Am J Respir Crit Care Med, 154 (1996), pp. 813-816
[7.]
M.L. Rubio, M.V. Sanchez-Cifuentes, M. Ortega, J. Escolar, G. Peces- Barba, N. Gonzalez Mangado.
N-acetylcysteine prevents cigarette smoke-induced small airways alterations in rats.
Eur Respir J, 15 (2000), pp. 505-511
[8.]
M.L. Rubio, M.V. Sanchez-Cifuentes, J. Escolar, G. Peces-Barba, N. Gonzalez Mangado.
Pulmonary collagen quantified in situ in two models of induced emphysema in rats.
Eur Respir J, 9 (1996), pp. S332
[9.]
M.L. Rubio, M.V. Sanchez-Cifuentes, G. Peces-Barba, S. Verbanck, M. Paiva, N. Gonzalez Mangado.
Intrapulmonary gas mixing in panacinar and centriacinar induced emphysema in rats.
Am J Respir Crit Care Med, 157 (1998), pp. 237-245
[10.]
S.I. Hagiwara, Y. Ishii, S. Kitamura.
Aerosolized administration of N-acetylcystgeine attenuates lung fibrosis induced by bleomycin in mice.
Am J Respir Crit Care Med, 162 (2000), pp. 225-231
[11.]
J. Cortijo, M. Cerda-nicolas, A. Serrano, G. Bioque, J.M. Estrela, F. Santangelo, et al.
Attenuation by oral N-acetylcysteine of bleomycin- induced lung injury in rats.
Eur Respir J, (2001),
[12.]
M. Ortega, M.L. Rubio, M.C. Martin Mosquero, M.V. Sanchez-Cifuentes, G. Peces-Barba, N. Gonzalez Mangado.
Kinetics of extracelular matrix proteins expression after instillation of cadmium chloride into the rat lung Eur Respir J, 14 (1999), pp. S297
[13.]
M. Kasielski, A. Antezak, M. Krol, D. Nowak.
Long-term treatment with N-acetylcysteine suppresses H2O2 exhalation in subjects with COPD.
Eur Respir J, 14 (1999), pp. S253
[14.]
G.C. Riise, I. Qvarfordt, S. Larsson, V. Eliasson, B.A. Andersson.
Inhibitori Effect of N-acetylcysteine on adhrence of Streptococcus pneumoniae and Haemophilus influenciae to human oropharyngeal epithelial cells in vitro.
Respiration, 67 (2000), pp. 552-558
[15.]
E. Straface, P. Matarrese, L. Gambardella.
N-acetylcysteine counteracts erythrocyte alterattions in chronic obstructive pulmonary disease.
Biochem Biophys Res Comm, 279 (2000), pp. 552-556
[16.]
P.J. Poole, P.N. Black.
Mucolytic agents for chronic bronchitis.
The Cochrane Library, 3 (1999), pp. 1-17
[17.]
E.M. Grandjean, P.h. Berthet, R. Ruffmann, P.h. Leuenberger.
Efficacy of oral long-term N-acetylcysteine in chronic bronchopulmonary disease: A meta-analysis of published double-blind, placebocontrolled clinical trials.
Clin Ther, 22 (2000), pp. 209-221
[18.]
C. Stey, J. Steurer, S. Bachmann, T.C. Medici, M.R. Tramer.
The effect of oral N-acetylcysteine in chronic bronchitis: a quantitative systematic review.
Eur Respir J, 16 (2000), pp. 253-262
[19.]
Bandolier. N-acetylcysteine in chronic bronchitis. http://www.jr2.ox.ac.uk/Bandolier/index.html Allergy, Asthma, Respiratory, 20 de noviembre de 2000
[20.]
E.M. Grandjean, P.h. Berthet, R. Ruffmann, P.H. Leuenberger.
Costeffectiveness analysis of oral N-acetylcysteine as a preventive treatment in chronic bronchitis.
Pharmacol Res, 42 (2000), pp. 39-50
[21.]
R. Pela, A.M. Calcagni, S. Subiaco, P. Isidori, A. Tubaldi, C.M. Sanguinneti.
N-acetylcysteine reduces the exacerbation rate in patients with moderate to severe COPD.
Respiration, 66 (1999), pp. 495-500
[22.]
D. Nowak, L. Carati, M. Pirozynski.
Long-term administration of N-acetylcysteine reduces the number of acute exacerbation episodes in subjects with chronic obstructive pulmonary disease: report of the breathe study.
Eur Respir J, 14 (1999), pp. S381
[23.]
E. Houtmeyers, R. Gosselink, G. Gayan-ramirez, M. Decramer.
Effects of drugs on mucus clearance.
Eur Resp J, 14 (1999), pp. 452-467
[24.]
E. Monso, J. Ruiz, A. Rosell, J. Manterola, J. Fiz, J. Morera, et al.
Bacterial infection in chronic obstructive pulmonary disease.
Am J Respir Crit Care Med, 152 (1995), pp. 1316-1320
[25.]
J.M. Travaline, S. Sudarshan, B.G. Roy, F. Cordova, V. Leyenson, G.J. Criner.
Effect of N-acetylcysteine on human diaphragm strenght and fatigability.
Am J Respir Crit Care Med, 156 (1997), pp. 1567-1571
[26.]
S. De Flora, C. Grassi, L. Carati.
Attenuation of influenza-like symptomatology and improvement of cell-mediated immunity with long-term N-acetylcysteine treatment.
Eur Respir J, 10 (1997), pp. 1535-1541
[27.]
J.M. Madison, R.S. Irwin.
Chronic obstructive pulmonary disease.
Lancet, 352 (1998), pp. 467-473
[28.]
R.A. Pauwels, A.S. Buist, P.M. Calverley, C.R. Jenkins, S.S. Hurd.
Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease. Nhlbi/who global initiative for chronic obstructive lung disease (gold) workshop summary.
Am J Respir Crit Care Med, 163 (2001), pp. 1256-1276
[29.]
R. Rodriguez-roisin.
Toward a consensus definition for COPD exacerbations.
Chest, 117 (2000), pp. S398-S401
[30.]
J. Garcia-Aymerich, E. Barreriro, E. Farrero, R.M. Marrades, J. Morera, J.M. Anto.
y the EFRAM investigators. Patients hospitalized for COPD have a high prevalence of modifiable risk factors for exacerbation (EFRAM study).
Eur Respir J, 16 (2000), pp. 1037-1402
[31.]
M. Decraner, P.N.R. Dekhuijzen, T. Troosters, C. van Herwaarden, Molken Rutten-van, C.P.O. van Scjayck, et al.
The bronchitis randomised on NAC cost-utility study (BRONCUS). hypothesis and design.
Eur Respir J, 17 (2001), pp. 329-336
[32.]
J. Behr, J. Maier, B. Degenkolb, F. Krombach, C. Vogelmeier.
Antioxidative and clinical effects of high-dose N-acetylcysteine in fibrosing alsveolitis.
Am J Respir Crit Care Med,, 156 (1997), pp. 1897
Copyright © 2001. Sociedad Española de Neumología y Cirugía Torácica